source
- FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impactThe FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol. The drug arrives as new clinical guidelines encou…
- Mentari Therapeutics secures second $200M private placement to fund migraine program and advance reverse mergerMentari Therapeutics, a spin‑out focused on migraine treatments, announced it has arranged a second private‑placement financing of $200 million. The new capital will be used to advance its migrain…